Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Navidea Biopharmaceuticals Inc. | NAV3-35 | Rheumatoid Arthritis | Phase 2b | Enrollment Conclusion | oral | Immunology: Anti-TNF |
| Navidea Biopharmaceuticals Inc. | NAV3-32 (TC99m-tilmanocept) | Rheumatoid arthritis | Phase 2b | Data Released | Intravenous | Immunology: Anti-TNF |
| Nektar Therapeutics | Rezpegaldesleukin (LY3471851) - (REZOLVE-AA) | Severe to very severe alopecia areata (AA) | Phase 3 | Trial Planned | Subcutaneous | #N/A |
| Nektar Therapeutics | Bempegaldesleukin (NKTR-214) and KEYTRUDA (pembrolizumab) | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2/3 | Trial Completed | Intravenous | Oncology |
| Nektar Therapeutics | Rezpegaldesleukin (LY3471851) - (REZOLVE-AD) | Atopic Dermatitis | Phase 2b | Data Released | Subcutaneous | Immunology |
| Nektar Therapeutics | NKTR-255 | Locally advanced non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Nektar Therapeutics | Bempegaldesleukin (NKTR-214) and OPDIVO (nivolumab) - (PIVOT-10) | Urothelial cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Nektar Therapeutics | NKTR-255 with BAVENCIO (avelumab) - (JAVELIN) | Locally advanced or metastatic urothelial carcinoma (UC) | Phase 2 | Data Released | Intravenous | Oncology |
